文献速递慢性肾脏病血液净化与透析

卡格列净在CKD不同多重用药负担下疗效与安全性一致:CREDENCE试验

Efficacy and safety of canagliflozin are consistent across polypharmacy burden in CKD: the CREDENCE trial.
PubMed 文献 · Nephrol Dial Transplant · 2026-09-04

该研究为CREDENCE试验的事后分析,纳入4401例2型糖尿病合并CKD患者,按用药数量分为无多重用药、多重用药和超多重用药三组。结果显示卡格列净对肾脏和心血管结局的疗效在各组间一致,安全性无交互作用,且多重用药和超多重用药患者的绝对风险降低更大。

要点

  • 卡格列净的肾脏和心血管获益不受多重用药状态影响。
  • 多重用药和超多重用药患者住院及心血管事件的绝对风险降低更显著。
  • 多重用药本身不应成为限制SGLT2抑制剂使用的理由。

核心结论

  • 在2型糖尿病合并CKD患者中,卡格列净的疗效和安全性在不同多重用药状态下表现一致。
  • 多重用药或超多重用药患者住院和心血管事件的绝对风险降低估计更大。
  • 多重用药本身不应排除对适宜患者使用SGLT2抑制剂。

研究设计与样本

  • CREDENCE试验的事后分析,纳入4401例2型糖尿病合并CKD患者。
  • 按用药数量分为无多重用药(0-4种)、多重用药(5-9种)和超多重用药(≥10种)。
  • 使用Cox比例风险模型评估相对效应,Poisson回归评估绝对获益。

主要发现

  • 612例(14%)无多重用药,2404例(55%)多重用药,1385例(31%)超多重用药,平均用药数8.3种(SD 3.77)。
  • 卡格列净对肾脏和心血管结局的效应在各多重用药组间一致,安全性结局交互作用P值均>0.06。
  • 停药率随用药负担增加而升高,但卡格列净组低于安慰剂组,且不受多重用药状态影响(P-interaction=0.16)。
  • 全因住院、心衰住院或心血管死亡的发生率随用药负担增加,多重用药和超多重用药患者的绝对风险降低更大。

关键数值与推荐

  • 主要结局为血清肌酐加倍、肾衰竭或心血管/肾脏疾病死亡的复合终点。
  • 多重用药定义为5-9种药物,超多重用药定义为≥10种药物。

临床怎么用

  • 对于有适应症的2型糖尿病合并CKD患者,不应仅因多重用药而避免使用卡格列净等SGLT2抑制剂。
  • 多重用药患者使用卡格列净的绝对获益可能更大,但需关注停药风险。

局限性

  • 为事后分析,结果需前瞻性研究验证。
  • 多重用药分类基于基线用药数量,未动态评估用药变化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Polypharmacy in chronic kidney disease (CKD) is substantial. Clinicians and patients are often reluctant to add medications to already complex regimens, partly due to concerns about diminishing efficacy and increased adverse effects. We assessed whether efficacy and safety of canagliflozin is modified by polypharmacy status in patients with type 2 diabetes and CKD. METHODS: We conducted a post-hoc analysis of the CREDENCE trial, which evaluated the effects of canagliflozin on outcomes in patients with type 2 diabetes and CKD. Participants were categorized as no polypharmacy (0-4 medicines), polypharmacy (5-9 medicines), or hyperpolypharmacy (≥10 medicines). We assessed the relative effects of canagliflozin on clinical and safety outcomes by polypharmacy status using Cox proportional hazards models. We assessed absolute benefits using Poisson regression. The primary outcome was a composite of doubling of serum creatinine, kidney failure or death due to cardiovascular or kidney disease. RESULTS: Among 4401 participants, 612 (14%), 2404 (55%), and 1385 (31%) were categorized as no polypharmacy, polypharmacy and hyperpolypharmacy, respectively. Mean number of medications was 8.3 (SD 3.77). The effect of canagliflozin on kidney and cardiovascular outcomes was consistent irrespective of polypharmacy status, with no interaction observed for safety outcomes (all P-interaction > 0.06). Rates of treatment discontinuation increased with medication burden, but were lower with canagliflozin versus placebo, regardless of polypharmacy status (P-interaction = 0.16). Incidence of all-cause hospitalization, and heart failure hospitalization or cardiovascular death increased with higher medication burden, thus absolute risk reductions were estimated to be substantially greater in patients with polypharmacy and hyperpolypharmacy. CONCLUSION: Among patients with type 2 diabetes and CKD, the efficacy and safety of canagliflozin appears consistent regardless of polypharmacy status, with larger estimated absolute reductions in hospitalizations and cardiovascular events in those experiencing polypharmacy or hyperpolypharmacy. These findings suggest that polypharmacy alone should not preclude consideration of SGLT2 inhibitor therapy in patients with CKD and type 2 diabetes for whom treatment is otherwise indicated.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Yeung EK, Siriwardana A, Buizen L, et al. Efficacy and safety of canagliflozin are consistent across polypharmacy burden in CKD: the CREDENCE trial. Nephrol Dial Transplant. 2026. PMID: 42695992. doi:10.1093/ndt/gfag203

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。